Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > REGULATORY
REGULATORY
- Key Govt Council Sets Up 4 Subcommittees; Scraping of Insurance Coverage for OTC-Like Drugs Up for Discussion
September 4, 2013
- PAFSC Second Committee on Drugs to Discuss Hepatitis C Treatment Simeprevir at Meeting on September 13
September 3, 2013
- Diovan Panel Heats Up Over Future Course of Discussions; “Find Out Truth” vs “Identify Structural Flaws”
September 3, 2013
- MHLW Aims to Reduce Medical Expenditure by 1 Trillion Yen by FY2025 through Measures to Promote Generic Drug Use
September 2, 2013
- MHLW Adds Interstitial Pneumonia as Serious Adverse Reaction of Simponi
August 30, 2013
- 8% Sales Tax Will Be Tacked on Drug Market Prices, How It Will Be Shown Not Yet Agreed: MHLW Panel
August 30, 2013
- CSIMC’s DPC Subcommittee to Reconsider Use of Functional Evaluation Coefficient II to Evaluate Rate of Generic Drug Use
August 30, 2013
- MHLW’s Health Bureau to Seek 408.9 Billion Yen for 2014 Budget, 21.1 Billion for Infectious Disease Prevention
August 29, 2013
- HPB’s FY2014 Budget Request Earmarks Funds to Strength System of Hospitals that Accept All Emergency Patients
August 29, 2013
- University Hospitals Asked to Inspect Own Clinical Trials amid Diovan Jitters
August 28, 2013
- MHLW Budget Requests Feature 114.1 Billion Yen for Japan NIH, Drug Discovery Network
August 28, 2013
- MHLW’s Economic Affairs Division Honing in on “4th Round” of Distribution Reform; Era of Bundling Won’t Return
August 27, 2013
- Second Committee Recommends Approval for Japan’s First LABA/LAMA Combination Drug
August 27, 2013
- PMDA Provides Risk Information on 10 Ethical Drugs Currently Under Evaluation
August 27, 2013
- New Ethical Guidelines to Include Preventive Measures against Misconduct in Research: Health, Education Ministries’ Interim Report
August 26, 2013
- Council Calls for Sharper Price Reductions for Long-Listed Drugs, Increase in Operating Profit Rate When Using Cost Calculation Method
August 26, 2013
- Applicants Objected to Proposed NHI Prices for 16 APIs in April 2010-May 2013; Revisions Made for 5 APIs
August 26, 2013
- First Committee Recommends Approval of Takeda’s Anti-Obesity Drug OBLEAN, Other Products
August 26, 2013
- Bill Payer and Healthcare Reps Support MHLW Proposal to Reduce NHI Prices; Industry Reps Want a Hold on a Decision
August 26, 2013
- Pharma Industry to Give Opinions at CSIMC Subcommittee in Sept., Stand against Health Ministry’s Plan to Cut Drug Prices
August 26, 2013
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…